Previous 10 | Next 10 |
The following slide deck was published by Exagen Inc. in conjunction with this event. For further details see: Exagen (XGN) Investor Presentation - Slideshow
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following December investor confere...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, to...
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q3 2020 Earnings Call Nov 10, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q3 2020 Earnings Call Transcript
Exagen Inc. (XGN) Q3 2020 Results Conference Call November 10, 2020 04:30 PM ET Company Participants Mike Cavanaugh - IR Ron Rocca - President and CEO Kamal Adawi - CFO Mark Hazeltine - SVP, Finance & Corporate Development Conference Call Participants Chris Lin - Cowen Kyle Mikson - Canto...
Exagen (XGN): Q3 GAAP EPS of -$0.34 beats by $0.14.Revenue of $10.78M (+3.3% Y/Y) beats by $1.97M.Shares -0.04%.Press Release For further details see: Exagen EPS beats by $0.14, beats on revenue
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported financial results for the quarter ended September 30, 2020. Third Quarter Hi...
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the following November investor confere...
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today a new study in collaboration with Brigham and Women’s Hospital in Boston, MA...
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced that it will release financial results for the quarter ended September 30, 2020 aft...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...